Crizotinib

From Anvita Health Wiki

Contents 1 Indications 2 Dosage 3 Adverse-effects 4 Mechanism-of-action 5 More General Terms 6 References

Indications

• non small cell lung carcinoma with mutations in the anaplastic lymphoma kinase ( ALK) protein

Dosage

• 250 mg PO BID for 25 weeks or more

Adverse-effects

• nausea (55%) & vomiting (39%) most common
• hepatotoxicity (< 1%), may be fatal [2]

Mechanism-of-action

• selective, ATP- competitive, small molecule, orally bioavailable inhibitor of ALK & MET/HGF receptor tyrosine kinases [1]

More General Terms

• antineoplastic agent (chemotherapeutic agent)

References

1. Bang Y et al, Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s, 2010 (suppl; abstr 3) [1]
2. Drug-induced hepatotoxicity with fatal outcome has occurred with Xalkori (crizotinib) Pfizer Bulletin: Dec 29, 2011

crizotinib (Xalkori)